Prehabilitation May Benefit Older Men Initiating ADT for Prostate Cancer

Share this content:
Researchers evaluated the changes in physical function and geriatric health in older men with prostate cancer initiating ADT.
Researchers evaluated the changes in physical function and geriatric health in older men with prostate cancer initiating ADT.

Older men starting androgen deprivation therapy (ADT) for prostate cancer may have baseline vulnerabilities in geriatric health, but appear to face little immediate detriment after treatment initiation, according to researchers at the University of Colorado Cancer Center.

In a study published in the Journal of Clinical Oncology, investigators found changes in physical function appeared to occur within the first 3 months of ADT in nearly half of patients. They also found that early prehabilitation, even for men on short-term ADT, may be beneficial.

The researchers conducted a pilot study to evaluate the changes in physical function and geriatric health in older men with prostate cancer initiating ADT. The team used tests easily employed in routine clinical practice. The men were assessed every 3 months for up to 12 months.

The study included 17 men with a median age of 75 years (range, 67 to 85 years), 14 of whom had metastatic disease. The initial results of this ongoing study demonstrated that because many of these men show baseline vulnerability due to their age and cancer, ADT may lead to an immediate improvement in functioning. However, there could be greater improvements with interventions, according to the investigators.

Currently, interventions exist to support overall functioning in geriatric prostate cancer patients. However, these initial findings suggest that some patients might benefit from prehabilitation, starting physical interventions a few weeks before initiating ADT. 

Reference

1. Kessler ER, Flaig TW, Lam ET, et al. A pilot study of the effects of androgen deprivation therapy on physical function and comprehensive geriatric health in older men with prostate cancer. J Clin Oncol. 2017;35(suppl):abstr e16510.
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs